Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway

Oncogene

Volumn 34, Issue 28, 2015, Pages 3688-3699

  Nitta, R T ^a   Gholamin, S ^a   Feroze, A H ^a   Agarwal, M ^a   Cheshier, S H ^a   Mitra, S S ^a   Li, G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,5,6,7-TETRABROMOBENZIMIDAZOLE; 5-(3-CHLOROPHENYLAMINO)BENZO(C)(2,6)NAPHTHYRIDINE-8-CARBOXYLIC ACID; BENZIMIDAZOLE DERIVATIVE; BETA CATENIN; CASEIN KINASE II; NAPHTHYRIDINE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; CANCER STEM CELL; CANCER TRANSPLANTATION; CELL PROLIFERATION; GENETICS; GLIOBLASTOMA; HUMAN; METABOLISM; MOUSE; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ANIMALS; BENZIMIDAZOLES; BETA CATENIN; BRAIN NEOPLASMS; CASEIN KINASE II; CELL LINE, TUMOR; CELL PROLIFERATION; GLIOBLASTOMA; HUMANS; MICE; NAPHTHYRIDINES; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 84954027323     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.299     Document Type: Article

References (48)

1. Louis D, Ohgaki H, Wiestler O, Cavanee W. Glioblastoma. In: Louis D, Ohgaki H, Wiestler O, Cavanee W (eds). WHO Classification of Tumours of the Central Nervous System. IARC Press: Paris, 1997, pp 33-49.
2. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
3. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
4. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
5. Litchfield DW. Protein kinase CK2: Structure, regulation and role in cellular decisions of life and death. Biochem J 2003; 369(Pt 1): 1-15.
6. Trembley JH, Chen Z, Unger G, Slaton J, Kren BT, Van WC et al. Emergence of protein kinase CK2 as a key target in cancer therapy. Biofactors 2010; 36: 187-195.
7. Prudent R, Moucadel V, Nguyen CH, Barette C, Schmidt F, Florent JC et al. Antitumor activity of pyridocarbazole and benzopyridoindole derivatives that inhibit protein kinase CK2. Cancer Res 2010; 70: 9865-9874.
8. Moucadel V, Prudent R, Sautel CF, Teillet F, Barette C, Lafanechere L et al. Antitumoral activity of allosteric inhibitors of protein kinase CK2. Oncotarget 2011; 2: 997-1010.
9. Olsen BB, Issinger OG, Guerra B. Regulation of DNA-dependent protein kinase by protein kinase CK2 in human glioblastoma cells. Oncogene 2010; 29: 6016-6026.
10. Zheng Y, McFarland BC, Drygin D, Yu H, Bellis SL, Kim H et al. Targeting protein kinase CK2 suppresses pro-survival signaling pathways and growth of glioblastoma. Clin Cancer Res 2013; 19: 6484-6494.
11. Dixit D, Sharma V, Ghosh S, Mehta VS, Sen E. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFalpha)-induced apoptosis through SIRT1 inhibition. Cell Death Dis 2012; 3: E271.
12. Cheong JW, Min YH, Eom JI, Kim SJ, Jeung HK, Kim JS. Inhibition of CK2{alpha} and PI3K/Akt synergistically induces apoptosis of CD34?leukaemia cells while sparing haematopoietic stem cells. Anticancer Res 2010; 30: 4625-4634.
13. Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ, Hu LM et al. Inhibition of CK2alpha down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS One 2012; 7: E38996.
14. Huillard E, Ziercher L, Blond O, Wong M, Deloulme JC, Souchelnytskyi S et al. Disruption of CK2beta in embryonic neural stem cells compromises proliferation and oligodendrogenesis in the mouse telencephalon. Mol Cell Biol 2010; 30: 2737-2749.
15. Ji H, Wang J, Nika H, Hawke D, Keezer S, Ge Q et al. EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell 2009; 36: 547-559.
16. Ponce DP, Yefi R, Cabello P, Maturana JL, Niechi I, Silva E et al. CK2 functionally interacts with AKT/PKB to promote the beta-catenin-dependent expression of survivin and enhance cell survival. Mol Cell Biochem 2011; 356: 127-132.
17. Ponce DP, Maturana JL, Cabello P, Yefi R, Niechi I, Silva E et al. Phosphorylation of AKT/PKB by CK2 is necessary for the AKT-dependent up-regulation of betacatenin transcriptional activity. J Cell Physiol 2011; 226: 1953-1959.
18. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF et al. Stem cellrelated "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008; 26: 3015-3024.
19. Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, Farooqi HK et al. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics 2008; 1: 52.
20. Prudent R, Sautel CF, Moucadel V, Laudet B, Filhol O, Cochet C. In vitro and in vivo assays of protein kinase CK2 activity. Methods Enzymol 2010; 485: 597-610.
21. Grigoryan T, Wend P, Klaus A, Birchmeier W. Deciphering the function of canonical Wnt signals in development and disease: Conditional loss-and gain-offunction mutations of beta-catenin in mice. Genes Dev 2008; 22: 2308-2341.
22. Nager M, Bhardwaj D, Canti C, Medina L, Nogues P, Herreros J. beta-Catenin signalling in glioblastoma multiforme and glioma-initiating cells. Chemother Res Pract 2012; 2012: 192362.
23. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403.
24. Beier CP, Beier D. CD133 negative cancer stem cells in glioblastoma. Front Biosci (Elite Ed) 2011; 3: 701-710.
25. He J, Liu Y, Lubman DM. Targeting glioblastoma stem cells: Cell surface markers. Curr Med Chem 2012; 19: 6050-6055.
26. Hu Y, Smyth GK. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009; 347: 70-78.
27. D'Amour KA, Gage FH. Are somatic stem cells pluripotent or lineage-restricted? Nat Med 2002; 8: 213-214.
28. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
29. Dalerba P, Clarke MF. Cancer stem cells and tumor metastasis: First steps into uncharted territory. Cell Stem Cell 2007; 1: 241-242.
30. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
31. Ikushima H, Todo T, Ino Y, Takahashi M, Saito N, Miyazawa K et al. Glioma-initiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein. J Biol Chem 2011; 286: 41434-41441.
32. Zbinden M, Duquet A, Lorente-Trigos A, Ngwabyt SN, Borges I, Altaba A. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J 2010; 29: 2659-2674.
33. Song DH, Dominguez I, Mizuno J, Kaut M, Mohr SC, Seldin DC. CK2 phosphorylation of the armadillo repeat region of beta-catenin potentiates Wnt signaling. J Biol Chem 2003; 278: 24018-24025.
34. Ponce DP, Yefi R, Cabello P, Maturana JL, Niechi I, Silva E et al. CK2 functionally interacts with AKT/PKB to promote the beta-catenin-dependent expression of survivin and enhance cell survival. Mol Cell Biochem 2011; 356: 127-132.
35. Clement V, Sanchez P, De Tribolet N, Radovanovic I, Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007; 17: 165-172.
36. Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci 2009; 29: 8884-8896.
37. Adesina AM, Lopez-Terrada D, Wong KK, Gunaratne P, Nguyen Y, Pulliam J et al. Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol 2009; 40: 843-853.
38. Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 2003; 425: 962-967.
39. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 2002; 99: 507-512.
40. Pierfelice TJ, Schreck KC, Eberhart CG, Gaiano N. Notch, neural stem cells, and brain tumors. Cold Spring Harb Symp Quant Biol 2008; 73: 367-375.
41. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006; 66: 7445-7452.
42. Androutsellis-Theotokis A, Leker RR, Soldner F, Hoeppner DJ, Ravin R, Poser SW et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 2006; 442: 823-826.
43. Zhang S, Long H, Yang YL, Wang Y, Hsieh D, Li W et al. Inhibition of CK2alpha down-regulates Notch1 signalling in lung cancer cells. J Cell Mol Med 2013; 17: 854-862.
44. Pagano MA, Bain J, Kazimierczuk Z, Sarno S, Ruzzene M, Di MG et al. The selectivity of inhibitors of protein kinase CK2: An update. Biochem J 2008; 415: 353-365.
45. Son YH, Song JS, Kim SH, Kim J. Pharmacokinetic characterization of CK2 inhibitor CX-4945. Arch Pharm Res 2013; 36: 840-845.
46. Nitta RT, Del Vecchio CA, Chu AH, Mitra SS, Godwin AK, Wong AJ. The role of the c-Jun N-terminal kinase 2-alpha-isoform in non-small cell lung carcinoma tumorigenesis. Oncogene 2011; 30: 234-244.
47. Nitta RT, Badal SS, Wong AJ. Measuring the constitutive activation of c-Jun N-terminal kinase isoforms. Methods Enzymol 2010; 484: 531-548.
48. Del Vecchio CA, Jensen KC, Nitta RT, Shain AH, Giacomini CP, Wong AJ. Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma. Cancer Res 2012; 72: 2657-2671.